Abstracts tagged "cytokines"

Abstract Number: L03 • ACR Convergence 2024
CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus
Kyleigh Brimmer¹, Olivia Antao¹, Daniel Mayer¹, Gina Sanchez¹, Rebecca Francis¹, Htay Htay Kyi², Mary Salim², Boyan Xia², Eugenio Capitle² and Jason Weinstein¹, ¹Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, ²Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
Abstract Number: L06 • ACR Convergence 2024
Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Subtypes of Inflammatory Myopathies
Raphael Kirou¹, Iago Pinal-Fernandez¹ and Andrew Mammen², ¹NIAMS/National Institutes of Health, Bethesda, MD, ²NIH, Bethesda, MD
Background/Purpose: Myositis is a term for a heterogeneous group of inflammatory myopathies, each with characteristic clinical manifestations, histopathological features, and autoantibodies, including myositis-specific autoantibodies (MSAs).…
Abstract Number: L18 • ACR Convergence 2024
CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis
Wei Guo¹, Zhaohua Li², Dan Xu² and Rong Mu², ¹Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, ²Peking University Third Hospital, Beijing, China
Background/Purpose: Understanding the roles of diverse fibroblast subsets is of great importance in elucidating the pathogenesis of fibrosis in systemic sclerosis (SSc). However, how the…
Abstract Number: 0605 • ACR Convergence 2024
Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
Dennis McGonagle¹, Raja Atreya², Maria Abreu³, James Krueger⁴, Kilian Eyerich⁵, Robert Bissonnette⁶, Carrie Greving⁷, He Li⁸, Tom C. Freeman⁹, Amy Hart⁸, Brice Keyes⁷, Brian Stoveken⁸, John Hartman⁸, Kristin Leppard⁸, Jenna Parrett¹⁰, Joshua Wertheimer⁸, Indra Sarabia⁷, Janise Deming⁷, Kristen Kohler⁷, Christopher Ritchlin¹¹, Iain McInnes¹², Matthieu Allez¹³, Anne Fourie⁷ and Kacey Sachen⁷, ¹National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom, ²Department of Medicine I, Gastroenterology, Endocrinology and Pneumology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ³Leonard M. Miller School of Medicine, University of Miami, Miami, FL, ⁴The Rockefeller University, Laboratory for Investigative Dermatology, New York, NY, ⁵Karolinska Institute, Department of Medicine – Division of Dermatology and Venereology, Stockholm, Sweden; Medical Center, University of Freiburg, Freiburg, Germany, ⁶Innovaderm Research Inc., Montréal, QC, Canada, ⁷Janssen Research & Development, LLC, Immunology, San Diego, CA, ⁸Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁹Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ¹⁰Janssen Scientific Affairs, LLC, Horsham, PA, ¹¹Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ¹²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ¹³Hôpital Saint-Louis, Université Paris Cité, Paris, France
Background/Purpose: IL-23 is implicated in the pathogenesis of psoriasis (PsO), and myeloid cells that express FcγRI (CD64) have been identified as a primary source of…
Abstract Number: 1496 • ACR Convergence 2024
Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
Loqmane seridi¹, Steven Leonardo², Brittney Scott³, Robert Gordon¹, cathye shu¹, Kaiyin Fei¹, Kim Lo³, Anne Stevens¹ and Sheng Gao³, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, ³Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA
Background/Purpose: SLE is a heterogeneous autoimmune disease affecting multiple organ systems, making clinical trial design challenging. Biomarkers that can identify patients with specific clinical manifestations…
Abstract Number: 1848 • ACR Convergence 2024
Characterization of Treg Phenotype, Function and Its Transcriptome Signatures in Treatment-naïve Rheumatoid Arthritis
Vallayyachari Kommoju¹, Sree Nethra Bulusu², Shruthi S Vembar³, Chengappa Kavadichanda⁴, Molly Thabah⁵, Christina Mary Mariaselvam² and Vir Singh Negi⁶, ¹JIPMER, Pondicherry, India, ²JIPMER, Pondicherry, Puducherry, India, ³IGIB, Bengalore, India, ⁴Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁵Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Puducherry, India, ⁶AIIMS, Bilaspur, Puducherry, Puducherry, India
Background/Purpose: Inflammatory cytokines in the periphery can affect Treg stability and function by altering its molecular signatures. We aimed to characterize Treg phenotype, function and…
Abstract Number: 0623 • ACR Convergence 2024
Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus
Melissa Munroe¹, Daniele DeFreese², Adrian Holloway², Mohan Purushothaman², Wade DeJager³, Susan Macwana³, Joel Guthridge⁴, Stan Kamp³, Nancy Redinger³, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yanfeng Li⁵, hu Zeng⁵, Uma Thanarajasingam⁵, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester
Background/Purpose: We have recently validated a plasma Lupus Flare Risk Index (L-FRI; Munroe et al. Ann Rheum Dis. 2024. 83 [Supp 1]: 402) and Lupus…
Abstract Number: 1504 • ACR Convergence 2024
Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6
Emma Neary¹, Carolina Munoz-Grajales², Joan Wither³, Juan Pablo Diaz Martinez³, Michelle Barraclough⁴, Kathleen Bingham³, Roberta Kretzmann³, Maria Carmela Tartaglia⁵, Lesley Ruttan⁶, May Choi⁷, Simone Appenzeller⁸, Sherief Marzouk³, Dennisse Bonilla³, Patti Katz⁹, Dorcas Beaton¹⁰, Robin Green³, Laura Patricia Whittall Garcia³, Dafna Gladman¹¹ and Zahi Touma¹², ¹McGill University, Montreal, QC, Canada, ²UHN/TWH, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The University of Manchester, Manchester, United Kingdom, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Toronto Rehab/University Health Network - University Centre, Toronto, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, SP, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada

Background/Purpose: Cognitive impairment (CI) is an increasingly prevalent neuropsychiatric manifestation in patients with systemic lupus erythematosus (SLE). Although CI has been identified through patient-reported outcomes…
Abstract Number: 1854 • ACR Convergence 2024
TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases
Christopher VanDeusen¹, Shannon Dwyer², Aldo Borroto³, Andres Gagete¹, D Scott Batty Jr¹ and Balbino Alarcon³, ¹Artax Biopharma, Inc, Cambridge, MA, ²Artax Biopharma, Inc., Cambridge, ³Centro de Biología Molecular Severo Ochoa, Madrid, Spain
Background/Purpose: Loss of T-cell tolerance to self-antigens underlies the development of all autoimmune diseases, and despite progress, there remains a significant unmet need for patients.…
Abstract Number: 0829 • ACR Convergence 2024
Epstein-Barr Virus Infection Triggers Hyperinflammation and Cytokine Storm in Healthy Children
Kailey Brodeur¹, Meng Liu², Rachel Weng², Evan Hsu², Lauren Henderson³, Fatma Dedeoglu², Jane Newburger³, Peter Nigrovic⁴, Mary Beth Son⁴ and Pui Lee⁵, ¹Boston Children's Hospital, Cumberland, RI, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, Watertown, MA, ⁴Boston Children's Hospital, Brookline, MA, ⁵Boston Children's Hospital, Newton, MA
Background/Purpose: Epstein-Barr virus (EBV) is common pathogen responsible for infectious mononucleosis but also triggers hemophagocytic lymphohistiocytosis (HLH). This variation in the immune response to EBV…
Abstract Number: 1579 • ACR Convergence 2024
Exploring the Cardiovascular Complications of Pulmonary Arterial Hypertension in Individuals with Systemic Sclerosis
Omar Mourad¹, Saif Abu Baker¹, Georges Khattar², Jennifer Jdaidani³, Khalil El-Gharib³ and Ahmad Mustafa³, ¹Staten Island University Hospital- Northwell Health, Staten Island, NY, ²Staten Island University Hospital, Staten Island, NY, ³Staten Island University Hospital- Northwell Health, Staten Island
Background/Purpose: Systemic sclerosis (SS) is a complex autoimmune rheumatic disease characterized by immune-mediated activation of both innate and adaptive immunity. Pulmonary involvement, specifically pulmonary arterial…
Abstract Number: 1860 • ACR Convergence 2024
Targeting Th1 Effector Cytokines, TNF-α and IFN-γ, Attenuates Experimental Autoimmune Myeloperoxidase ANCA Associated Vasculitis
Kei Nagai¹, Daniel Koo Yuk Cheong², Anh Cao-Le², Joshua Ooi³ and Poh Yi Gan², ¹Department of Nephrology, University of Tsukuba, Tsukuba, Ibaraki, Japan, ²Department of Medicine, Monash University, Melbourne, Victoria, Australia, ³Monash University-T Cell Therapies Research Group, Clayton, Victoria, Australia
Background/Purpose: Anti-cytokine monoclonal antibody (mAb) therapies have shown efficacy in numerous autoimmune diseases but have yet to succeed in myeloperoxidase anti-neutrophil cytoplasmic antibody associated vasculitis…
Abstract Number: 0860 • ACR Convergence 2024
Integrated Metabolic and Immunologic Analyses Reveal Distinctive Features of Comorbid Cancer in Patients with Autoimmune Diseases
Xiangyi Shen¹, Xu Jiang², Yangzhige He² and Huaxia Yang³, ¹Tsinghua University, Beijing, China, ²National Infrastructure for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: Autoimmune diseases (AIDs) increase the risk of cancer and impose a substantial socioeconomic burden worldwide. However, the biological characteristics of cancer as a comorbidity…
Abstract Number: 1594 • ACR Convergence 2024
Response to Mepolizumab Therapy in a Single-center Cohort of Eosinophilic Granulomatosis with Polyangiitis Patients: Characterization of Cytokine/Chemokine Pattern and Phenotypic Stratification
Michele Moretti¹, Francesco Ferro², Irene Martelli³, Francesca Pistone³, Giulia Greco³, Federica Di Cianni⁴, Nazzareno Italiano⁵, ROSARIA TALARICO⁴, Veronica Seccia⁶, Chiara Baldini⁷, Ilaria Puxeddu³ and Marta Mosca⁷, ¹University of Pisa, Pisa, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁴University of Pisa, Pisa, Italy, ⁵University of Pisa, Rovigo, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ⁷University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy
Background/Purpose: The introduction of Mepolizumab treatment has revolutionized the therapy of EGPA and has promoted the search for biomarkers predictive of response to treatment. However,…
Abstract Number: 1993 • ACR Convergence 2024
Identification of Elevated Soluble Factors in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Their Association with Severity and Persistence
Elise Gray-Gaillard¹, Clifton Bingham¹, Ami Shah² and Laura Cappelli³, ¹Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICI) are a type of cancer immunotherapy being implemented as the standard of care for an increasing number of malignancies. Due…

1
2
3
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].